Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology [Yahoo! Finance]
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience (NYSE:ANRO) had its price target raised by analysts at Chardan Capital from $15.00 to $30.00. They now have a "buy" rating on the stock.